WO2010139979A2 - Procédés d'élaboration de formes cristallines - Google Patents

Procédés d'élaboration de formes cristallines Download PDF

Info

Publication number
WO2010139979A2
WO2010139979A2 PCT/GB2010/050892 GB2010050892W WO2010139979A2 WO 2010139979 A2 WO2010139979 A2 WO 2010139979A2 GB 2010050892 W GB2010050892 W GB 2010050892W WO 2010139979 A2 WO2010139979 A2 WO 2010139979A2
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
process according
anhydrous
dcm
monohydrate
Prior art date
Application number
PCT/GB2010/050892
Other languages
English (en)
Other versions
WO2010139979A3 (fr
Inventor
Vinayak Govind Gore
Laxmikant Patkar
Amit Bagul
Priyesh Surendra Vijaykar
Mahesh Edake
Original Assignee
Generics [Uk] Limited
Mylan India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics [Uk] Limited, Mylan India Private Limited filed Critical Generics [Uk] Limited
Publication of WO2010139979A2 publication Critical patent/WO2010139979A2/fr
Publication of WO2010139979A3 publication Critical patent/WO2010139979A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to intermediates and their preparation, for use in the manufacture of pure dasatinib, in particularly dasatinib monohydrate and anhydrous dasatinib.
  • the invention also relates to pharmaceutical compositions comprising pure dasatinib and their use in the treatment of cancer.
  • Dasatinib is an active pharmaceutical ingredient approved for the treatment of cancer, in particular treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. Dasatinib is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
  • CML chronic myeloid leukaemia
  • ALL Philadelphia chromosome positive
  • ALL acute lymphoblastic leukaemia
  • lymphoid blast CML lymphoid blast CML with resistance or intolerance to prior therapy.
  • Scheme 1 shows a general process for the preparation of dasatinib as disclosed in US 2006/0004067.
  • Intermediate 3 and N-(2-hydroxyethyl)piperazine (HEP) are heated together in a solvent system comprising n-butanol as a solvent and diisopropylethylamine (DIPEA) as a base.
  • DIPEA diisopropylethylamine
  • dasatinib precipitates out and is isolated by filtration.
  • Further processing into the monohydrate form was achieved in a number of ways, for example, forming dasatinib acetate and heating, or heating dasatinib in an aqueous ethanol solution.
  • the object of the invention is to provide novel intermediates that can be used in the preparation of dasatinib with a purity of greater than 99.7%.
  • the intermediates may be used to prepare anhydrous dasatinib and dasatinib monohydrate.
  • Preparing API with increased purity is always an aim of the pharmaceutical development team.
  • the inventors have found that preparing dasatinib monohydrate or anhydrous dasatinib using a dichloromethane (DCM) solvated dasatinib intermediate resulted in a particularly pure product with a good yield.
  • DCM dichloromethane
  • a process for preparing dasatinib dichloromethane solvate comprising: (i) mixing an intermediate having structure 3 - A -
  • the intermediate 3 is suspended in a solvent system comprising one or more organic solvents.
  • the solvent system could comprise one or more of dimethyl sulphoxide (DMSO), dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP) and dimethylacetamide (DMAC).
  • the solvent system comprises DMSO.
  • DMSO dimethyl sulphoxide
  • NMP N-methyl-2-pyrrolidone
  • DMAC dimethylacetamide
  • the solvent system comprises DMSO.
  • DMSO dimethyl sulphoxide
  • NMP N-methyl-2-pyrrolidone
  • DMAC dimethylacetamide
  • a molar ratio of intermediate 3 : HEP of about 1 :2 or about 1:3 is particularly advantageous.
  • HEP acting as the base serves to trap HCl that is liberated during the reaction. It has been found that this ratio is particularly advantageous and provides a particularly pure product with high yield.
  • the invention is also enabled and high purity product is prepared in embodiments wherein the ratio of intermediate 3 : HEP is between about 1:1 to about 1:50, preferably between about 1:2 to about 1:10, or in certain embodiments between about 1:2 to about 1:5, particularly 1:2 or 1:3.
  • the inventors have found that dissolving the intermediate 3, either partially or completely, provides a particularly pure product.
  • the skilled person will realise that there are a number of means by which dissolution can be effected.
  • the mixture may be sonicated or subjected to stirring.
  • the inventors found that in particularly preferred embodiments the mixture may be heated until clear.
  • the inventors also found that DMSO is the preferred solvent.
  • the intermediate 3 / HEP mixture is heated to about 60-65 0 C for between about 1-24 hours, most preferably 5-10 hours.
  • the heating conditions may differ, but are within the skill set of the skilled person to determine.
  • the HEP is utilised as the solvent, the base and the reactant. In these embodiments further solvents are not utilised.
  • a particularly preferred embodiment comprises a process according to the first aspect of the invention, wherein the reaction mixture is allowed to cool before the anti-solvent is added, most preferably the solution is allowed to cool to about 20-30 0 C.
  • Further preferred embodiments provide a process according to the first aspect, wherein between about 10 to 50 volumes, preferably between about 15 to 30 volumes, of anti- solvent with respect to intermediate 3 are added to the reaction mixture in step (ii). Most preferably about 21 volumes of anti-solvent are added. The inventors found that this ratio of anti-solvent : intermediate 3 was particularly advantageous in preparing a pure product with good yield.
  • the anti-solvent comprises DCM and in particularly preferred embodiments further comprises water.
  • the water is present in a ratio of DCM : water of between about 1:4 to 4:1, most preferably the ratio is about 1:1.
  • a ratio of about 1:1 provides a particularly pure product.
  • the inventors determined that in certain embodiments the water can be added to the DCM before both are added to the reaction mixture or may be added to the reaction mixture independently of the DCM and the reaction still be within the spirit and scope of the invention.
  • Further preferred embodiments comprise a process for preparing dasatinib DCM solvate, wherein the precipitated solid from step (iii) is isolated.
  • the precipitated solid may be isolated.
  • Certain embodiments comprise isolating the precipitated solid by allowing the solvent to evaporate.
  • the precipitated solid dasatinib DCM solvate is isolated by filtration.
  • the filtered solid can then be allowed to dry in ambient conditions or in particularly preferred embodiments the filtered solid is further dried at between about 25- 65°C for about 8-12 hours or in alternative embodiments until a constant weight is achieved.
  • the inventors have found that drying under the preferred conditions does not cause degradation of the isolated dasatinib solvate or conversion to another polymorphic form.
  • the process according to the invention results in particularly pure product.
  • the chemical purity can be as high as 99.5%.
  • the solvent system comprises one of DMSO, THF, and DCM or any combination thereof.
  • the preferred solvents may by utilised in a number of different configurations.
  • the sequence of addition of the solvents for further purifying the dasatinib DCM solvate comprises:
  • the solid may be dissolved in a number of ways, which in some embodiments comprises heating or sonication, but in most preferable embodiments the solid is stirred until the DMSO is clear indicating complete dissolution of the dasatinib DCM solvate.
  • the solid is stirred for about 5-10 minutes at ambient temperatures, most preferably between about 20-30 0 C.
  • Further preferred embodiments comprise a process for further purifying the dasatinib DCM solvate, wherein the precipitated solid from step (d) is isolated.
  • the precipitated solid may be isolated.
  • Certain embodiments comprise isolating the precipitated solid by allowing the solvent to evaporate.
  • the further purified precipitated solid dasatinib DCM solvate from step (d) is isolated by filtration.
  • the filtered solid can then be allowed to dry in ambient conditions or in particularly preferred embodiments the filtered solid is further dried at between about 25-65°C for about 8-12 hours or in alternative embodiments until a constant weight is achieved.
  • the inventors have found that drying under the preferred conditions does not cause degradation of the isolated dasatinib solvate or conversion to another polymorphic form.
  • the further purified dasatinib DCM solvate is washed in DCM before it is dried, most preferably at between about 60-65 0 C for about 8- 12 hours. Dasatinib DCM solvate so purified was found to be greater than 99.8% pure as determined by HPLC.
  • the pure dasatinib DCM solvate may be used to prepare pure anhydrous dasatinib or dasatinib monohydrate of increased purity. Accordingly there is provided in a second aspect of the invention a process for preparing anhydrous dasatinib comprising desolvating dasatinib DCM solvate.
  • the DCM solvate is prepared by a process according to the first aspect of the invention.
  • the anhydrous dasatinib is prepared by heating the dasatinib DCM solvate in acetonitrile and isolating the anhydrous dasatinib.
  • the dasatinib DCM solvate / acetonitrile mixture is heated to between about 50- 85°C for about 5-72 hours.
  • the dasatinib DCM solvate / acetonitrile mixture is heated to between about 60-85 0 C or about 80-85 0 C for about 6-8 hours.
  • the anhydrous dasatinib may be isolated by any of a number of means including allowing the solvent to evaporate.
  • the mixture is allowed to cool until anhydrous dasatinib precipitate is formed and the anhydrous dasatinib is isolated, preferably by filtration, and is preferably further washed in acetonitrile.
  • the filtered anhydrous dasatinib can then be allowed to dry in ambient conditions or in particularly preferred embodiments the filtered solid is dried at between about 60-65 0 C for about 8-12 hours or in alternative embodiments until a constant weight is achieved. The inventors have found that drying under the preferred conditions does not cause degradation of the isolated anhydrous dasatinib or conversion to another polymorphic form.
  • anhydrous dasatinib by recrystallising dasatinib DCM solvate from a combination of DMF (N 5 N- dimethylformamide) and toluene.
  • dasatinib dichloromethane solvate is provided.
  • a fourth aspect of the invention provides dasatinib dichloromethane solvate exhibiting an XRPD pattern substantially as shown in Figure 1.
  • a fifth aspect provides dasatinib dichloromethane solvate exhibiting a TGA pattern substantially as shown in Figure 2.
  • a sixth aspect provides dasatinib dichloromethane solvate exhibiting a DSC pattern substantially as shown in Figure 3.
  • dasatinib DCM solvate also provides pure dasatinib DCM solvate for example for use as an intermediate in preparing anhydrous dasatinib or dasatinib monohydrate.
  • the dasatinib DCM solvate so prepared has a purity of greater than 99.5%. Accordingly there is provided in a seventh aspect of the invention, dasatinib DCM solvate having a chemical purity of greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8%.
  • the dasatinib DCM solvate according to the invention or prepared by a process according to the invention has a chemical purity of greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8% (as measured by HLPC).
  • the dasatinib DCM solvate according to the invention or prepared by a process according to the invention has a polymorphic purity of greater than 95%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8% (as measured by XRPD).
  • An eighth aspect of the invention provides anhydrous dasatinib having a chemical purity of greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8%.
  • the anhydrous dasatinib according to the invention or prepared by a process according to the invention has a chemical purity of greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8% (as measured by HLPC).
  • the anhydrous dasatinib according to the invention or prepared by a process according to the invention has a polymorphic purity of greater than 95%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8% (as measured by XRPD).
  • a ninth aspect provides dasatinib monohydrate having a chemical purity of greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8%.
  • the dasatinib monohydrate according to the invention or prepared by a process according to the invention has a chemical purity of greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8% (as measured by HLPC).
  • the dasatinib monohydrate according to the invention or prepared by a process according to the invention has a polymorphic purity of greater than 95%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, most preferably greater than 99.8% (as measured by XRPD).
  • anhydrous dasatinib prepared by a process according to the second aspect of the invention or anhydrous dasatinib according to the eighth aspect of the invention is used.
  • the anhydrous dasatinib may be dissolved in the water in any of a number of ways. In preferred embodiments the anhydrous dasatinib may only be partially dissolved with the remainder of the dasatinib in suspension or in alternative embodiments the anhydrous dasatinib is substantially completely dissolved.
  • Dissolution may be effected in some embodiments by sonication or stirring.
  • the anhydrous dasatinib is substantially suspended in the water.
  • the inventors found however that heating the anhydrous dasatinib and water to be most effective. Accordingly in particularly preferred embodiments the anhydrous dasatinib and water are heated to between about 90-100 0 C, wherein the anhydrous dasatinib remains partially dissolved, but of course the skilled person will realise that further dissolution techniques may cause the anhydrous dasatinib to dissolve completely or substantially completely.
  • the anhydrous dasatinib and water are heated until the reaction mixture is clear.
  • the dasatinib monohydrate may then be isolated, preferably by cooling the reaction mixture, most preferably to between about 25-30 0 C, until the dasatinib monohydrate precipitates from the reaction mixture.
  • the dasatinib monohydrate is formed and isolated by filtration.
  • the filtered dasatinib monohydrate can then be allowed to dry in ambient conditions or in particularly preferred embodiments the filtered solid is dried at between about 60-65 0 C for about 8-12 hours or in alternative embodiments until a constant weight is achieved. The inventors have found that drying under the preferred conditions does not cause degradation of the isolated dasatinib monohydrate or conversion to another polymorphic form.
  • An eleventh aspect according to the invention provides a process for the conversion of dasatinib monohydrate to anhydrous dasatinib, comprising (i) heating dasatinib monohydrate in a solvent system comprising acetonitrile or (ii) heating dasatinib monohydrate in a solvent system comprising a combination of DMF and toluene and azeotropically removing the water.
  • a twelfth aspect of the invention provides a pharmaceutical composition comprising crystalline dasatinib monohydrate prepared by a process according to the tenth aspect of the invention or crystalline dasatinib monohydrate according to the ninth aspect of the invention and one or more pharmaceutically acceptable excipients.
  • a thirteenth aspect of the invention provides the use of a pharmaceutical composition according to the twelfth aspect of the invention in the treatment of cancer, most preferably in the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate or treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) or lymphoid blast CML with resistance or intolerance to prior therapy.
  • CML chronic myeloid leukaemia
  • ALL Philadelphia chromosome positive
  • ALL acute lymphoblastic leukaemia
  • lymphoid blast CML with resistance or intolerance to prior therapy.
  • a fourteenth aspect of the invention provides crystalline dasatinib monohydrate prepared by a process according to tenth aspect of the invention or crystalline dasatinib monohydrate according to the ninth aspect of the invention for use in the treatment of cancer, most preferably for use in the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate or treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) or lymphoid blast CML with resistance or intolerance to prior therapy.
  • CML chronic myeloid leukaemia
  • ALL Philadelphia chromosome positive
  • ALL acute lymphoblastic leukaemia
  • lymphoid blast CML with resistance or intolerance to prior therapy.
  • a fifteenth aspect of the invention provides a pharmaceutical composition comprising anhydrous dasatinib prepared by a process according to the second or eleventh aspect of the invention or anhydrous dasatinib according to the eighth aspect of the invention and one or more pharmaceutically acceptable excipients.
  • a sixteenth aspect of the invention provides the use of a pharmaceutical composition according to the fifteenth aspect of the invention in the treatment of cancer, most preferably in the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate or treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) or lymphoid blast CML with resistance or intolerance to prior therapy.
  • CML chronic myeloid leukaemia
  • ALL Philadelphia chromosome positive
  • ALL acute lymphoblastic leukaemia
  • lymphoid blast CML with resistance or intolerance to prior therapy.
  • a seventeenth aspect of the invention provides anhydrous dasatinib prepared by a process according to the second or eleventh aspect of the invention or anhydrous dasatinib according to the eighth aspect of the invention for use in the treatment of cancer, most preferably for use in the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate or treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) or lymphoid blast CMT, with resistance or intolerance to prior therapy.
  • CML chronic myeloid leukaemia
  • ALL Philadelphia chromosome positive
  • ALL acute lymphoblastic leukaemia
  • lymphoid blast CMT lymphoid blast CMT
  • An eighteenth aspect of the invention provides use of anhydrous dasatinib or crystalline dasatinib monohydrate according to the invention in the manufacture of a medicament for treating cancer.
  • the medicament is for treating adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate or for treating adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) or lymphoid blast CML with resistance or intolerance to prior therapy.
  • CML chronic myeloid leukaemia
  • ALL Philadelphia chromosome positive
  • ALL acute lymphoblastic leukaemia
  • lymphoid blast CML with resistance or intolerance to prior therapy.
  • a nineteenth aspect of the invention provides a method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of anhydrous dasatinib or crystalline dasatinib monohydrate according to the invention or a therapeutically effective amount of the pharmaceutical composition according to the invention.
  • the method is for treating adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate or for treating adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) or lymphoid blast CML with resistance or intolerance to prior therapy.
  • the patient is a mammal, preferably a human.
  • Figure 1 shows an XRP diffractogram of dasatinib DCM solvate according to the invention.
  • Figure 2 shows a thermogravimetric analysis (TGA) trace of dasatinib DCM solvate according to the invention.
  • Figure 3 shows a differential scanning calorimetry (DSC) trace of dasatinib DCM solvate according to the invention.
  • Figure 4 shows an XRP diffractogram of dasatinib DMSO solvate according to the invention.
  • FIG. 5 shows a thermogravimetric analysis (TGA) trace of dasatinib DMSO solvate according to the invention.
  • Figure 6 shows a differential scanning calorimetry (DSC) trace of dasatinib DMSO solvate according to the invention.
  • Figure 7 shows an XRP diffractogram of crystalline dasatinib monohydrate according to the invention.
  • FIG. 8 shows a thermogravimetric analysis (TGA) trace of crystalline dasatinib monohydrate according to the invention.
  • Figure 9 shows a differential scanning calorimetry (DSC) trace of crystalline dasatinib monohydrate according to the invention.
  • Figure 10 shows an XRP diffractogram of anhydrous dasatinib according to the invention.
  • FIG 11 shows a thermogravimetric analysis (TGA) trace of anhydrous dasatinib according to the invention.
  • FIG. 12 shows a differential scanning calorimetry (DSC) trace of anhydrous dasatinib according to the invention. Detailed description of the invention
  • reference to chemical purity refers to a compound having a purity of greater than 95%, including greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.5%, and greater than 99.8% as determined by HPLC.
  • anhydrous does not exclude the possibility of the presence of some water on or in the salt (e.g. a crystal of the salt). For example, there may be some water present on the surface of the salt (e.g. salt crystal), or minor amounts within the body of the salt (e.g. salt crystal).
  • an anhydrous form contains fewer than 0.4 molecules of water per molecule of compound, and more preferably contains fewer than 0.1 molecules of water per molecule of compound, for example 0 molecules of water.
  • Illustrative of the invention is a pharmaceutical composition made by mixing crystalline dasatinib monohydrate according to the invention and one or more pharmaceutically acceptable excipients.
  • Solid pharmaceutical compositions of the present invention include powders, granulates, aggregates and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
  • the dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts. Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and lozenges, as well as liquid syrups, suspensions and elixirs.
  • the dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or a soft shell.
  • the shell may be made from gelatin and optionally contain a plasticizer such as glycerine and sorbitol, and an opacifying agent or colourant.
  • the active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
  • a composition for tabletting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredient and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules.
  • the granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size.
  • the granulate may then be tabletted or other excipients may be added prior to tabletting, such as a glidant and/or a lubricant.
  • a tabletting composition may be prepared conventionally by dry granulation.
  • the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet.
  • a blended composition may be compressed directly into a compacted dosage form using direct compression techniques.
  • Direct compression produces a uniform tablet without granules.
  • Excipients that are particularly well suited for direct compression tabletting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tabletting is known to those in the art with experience and skill in particular formulation challenges of direct compression tabletting.
  • a capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tabletting, however, they are not subjected to a final tabletting step.
  • compositions of the invention may further comprise one or more additional active ingredients.
  • Example 2 A suspension of intermediate 3 (40 g, 1 equivalent) in DMSO (280 ml, 7 volumes) was heated to 60-65 0 C. To this solution, HEP (39.6 g, 3 equivalents) was added until the reaction mixture became clear. Heating was continued at the same temperature for 6 hours (reaction was monitored by TLC and HPLC). Then the reaction mixture was allowed to cool to 25-30 0 C and dichloromethane (840 ml, 21 volumes) was added and stirred for 1 hour until a white precipitate formed. The precipitate was separated by filtration and dried under suction for 15-20 minutes. The solid was dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid obtained weighed 30.2 g and had a purity (by HPLC) of 99.7%. The solid was determined by XRPD analysis to be dasatinib DCM solvate (see Figure 1).
  • Example 4 Further purification Dasatinib DCM solvate (40 g, 1 equivalent) obtained in example 2 was suspended in DMSO (200 ml, 5 volumes) and stirred at 25-30 0 C for 5-10 minutes until the solid completely dissolved. THF (80 ml, 2 volumes) was added at the same temperature and stirred for 5-10 minutes. Finally, DCM (500 ml, 12.5 volumes) was added at 25-30 0 C and the reaction mixture was stirred for 2 hours at 25-30 0 C. A white solid progressively precipitated out. The solid was separated by filtration, washed with DCM (200 ml, 5 volumes) and dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid obtained weighed 30.2 g and had a purity (by HPLC) of 99.7%. The solid was determined by XRPD analysis to be dasatinib DCM solvate (see Figure 1).
  • Dasatinib DCM solvate (28 g, 1 equivalent) obtained in example 3 was suspended in acetonitrile (280 ml, 10 volumes) and heated to 80-85 0 C for 6-8 hours. Then the suspension was cooled to 25-30 0 C, the resultant solid precipitate was filtered, washed with acetonitrile (56 ml, 2 volumes) and dried in a vacuum oven at 60-65 0 C for 8-12 hours.
  • the white solid obtained weighed 24 g, had a purity of 99.7% (as measured by HPLC) and was shown to be anhydrous dasatinib by XRPD and TGA (see Figures 10 and 11).
  • Example 6 Anhydrous dasatinib (5 g, 1 equivalent) was suspended in water (50 ml, 10 volumes). The suspension was heated to 98-100 0 C for 4 hours. On cooling to 25-30 0 C, a slurry formed which was filtered and dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid obtained weighed 4.7 g, had a purity of 99.5% (as measured by HPLC) and was shown to be dasatinib monohydrate by XRPD and TGA (see Figures 7 and 8).
  • Example 7 Anhydrous dasatinib (5 g, 1 equivalent) was suspended in DMSO (10 ml, 2 volumes). The suspension was heated to 45-50 0 C. A clear solution was observed. This clear solution was stirred at 45-50 0 C for 4-12 hours. On cooling to 25-30 0 C, a solid precipitate formed which was filtered and dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid obtained weighed 4.53 g, had a purity of 99.5% (as measured by HPLC) and was shown to be a DMSO solvate of dasatinib by XRPD and TGA (see Figures 4 and 5).
  • Example 8 Anhydrous dasatinib (3 g, 1 equivalent) was suspended in DCM (45 ml, 15 volumes). The suspension was heated to 38-40 0 C and was further stirred at 38-40 0 C for 8-12 hours. On cooling to 5-10 0 C, a slurry formed which was filtered, washed with DCM (6 ml, 2 volumes) and dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid obtained weighed 2.8 g, had a purity of 99.5% (as measured by HPLC) and was shown to be a dasatinib DCM solvate by XRPD and TGA (see Figures 1 and 2).
  • Example 9 Dasatinib monohydrate (10 g, 1 equivalent) was suspended in acetonitrile (150 ml, 15 volumes) and heated to 78-82°C for 8-12 hours. The suspension was cooled to 25-30 0 C. The resultant solid was filtered, washed with acetonitrile (20 ml, 2 volumes) and dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid weighed 8.5 g, had a purity of 99.5% (as measured by HPLC) and was shown to be anhydrous dasatinib by XRPD and TGA (see Figures 10 and 11).
  • Example 10 Dasatinib monohydrate (5 g, 1 equivalent) was suspended in DMF (100 ml, 20 volumes) and toluene (100 ml, 20 volumes) was added. The suspension was heated to 135-140 0 C on a Dean-Stark apparatus until the solution cleared. Water was collected over 24 hours. On cooling to 25-30 0 C, the resultant solid precipitate was filtered and dried in a vacuum oven at 60-65 0 C for 8-12 hours. The white solid weighed 4.2 g, had a purity of 99.5% (as measured by HPLC) and was shown to be anhydrous dasatinib by XRPD and TGA (see Figures 10 and 11).
  • the XRPDs were recorded on a Bruker D8 Advance Instrument (BRUKER AXS), using copper radiation as the X-ray source and LynxEye as the detector. Samples were placed on a silica background holder.
  • BRUKER AXS Bruker D8 Advance Instrument
  • the DSCs were recorded on a Perkin Elmer Pyris 1.
  • the DSC sample chamber was purged with 40 ml/min of ultra high purity indium. The accuracy of the measured sample temperature with this method is within about ⁇ 1°C.
  • the sample was placed into a closed aluminium DSC pan with pinhole. At least 2 mg of sample powder was placed in the pan and sealed.
  • the instrument was programmed to heat at a rate of 10 0 C per minute in the temperature range between 25°C and 350 0 C.
  • the TGAs were recorded on a Perkin Elmer Pyris 1. Samples of at least 10 mg were analysed at a heating rate of 10 0 C per minute in the temperature range between 25°C and about 350 0 C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des intermédiaires et leur élaboration, aux fins d'utilisation dans la fabrication de dasatinib pur, en particulier le monohydrate de dasatinib et le dasatinib anhydre. L'invention concerne aussi des compositions pharmaceutiques renfermant du dasatinib pur et leur utilisation dans le traitement du cancer.
PCT/GB2010/050892 2009-06-03 2010-05-28 Procédés d'élaboration de formes cristallines WO2010139979A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN828KO2009 2009-06-03
IN828/KOL/2009 2009-06-03
IN829KO2009 2009-06-03
IN829/KOL/2009 2009-06-03

Publications (2)

Publication Number Publication Date
WO2010139979A2 true WO2010139979A2 (fr) 2010-12-09
WO2010139979A3 WO2010139979A3 (fr) 2011-05-05

Family

ID=42734619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050892 WO2010139979A2 (fr) 2009-06-03 2010-05-28 Procédés d'élaboration de formes cristallines

Country Status (1)

Country Link
WO (1) WO2010139979A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102408423A (zh) * 2011-11-29 2012-04-11 上海希迪制药有限公司 一种制备大粒径达沙替尼的方法
US20120309968A1 (en) * 2010-02-08 2012-12-06 Nan Jing Cavendish Bio-Engineering Technology Co., Ltd. Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
WO2013065063A1 (fr) 2011-11-03 2013-05-10 Cadila Healthcare Limited Forme anhydre du dasatinib, son procédé de préparation et son utilisation
WO2013078973A1 (fr) * 2011-11-29 2013-06-06 上海创诺制药有限公司 Dasatinib à grand diamètre des particules et sa préparation et son utilisation
WO2013157019A2 (fr) * 2012-04-20 2013-10-24 Shilpa Medicare Ltd. Procédé pour la préparation de dasatinib monohydraté
CN103408542A (zh) * 2013-08-13 2013-11-27 南京优科生物医药研究有限公司 一种高纯度的达沙替尼无水物的制备方法
CN103709156A (zh) * 2012-09-29 2014-04-09 石药集团中奇制药技术（石家庄）有限公司 一种达沙替尼多晶型药物及其制备方法
WO2014086326A1 (fr) * 2012-12-06 2014-06-12 Zentiva, K.S. Procédé pour la préparation et la purification de polymorphes et solvates nouveaux et connus du dasatinib
WO2015107545A1 (fr) * 2013-12-18 2015-07-23 Dharmesh Mahendrabhai Shah Sels solubles dans l'eau d'hydrate de dasatinib
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
WO2018100585A1 (fr) * 2016-12-01 2018-06-07 Natco Pharma Limited Procédé amélioré de préparation de polymorphe de dasatinib
WO2019209908A1 (fr) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Formes cristallines de dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007035874A1 (fr) 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Administration par voie orale de n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide et sels de celui-ci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539156A (ja) * 2007-10-23 2010-12-16 テバ ファーマシューティカル インダストリーズ リミティド ダサチニブ多形体およびその調製プロセス

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007035874A1 (fr) 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Administration par voie orale de n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide et sels de celui-ci

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884013B2 (en) * 2010-02-08 2014-11-11 Nan Jing Cavendish Bio-Engineering Technology Co., Ltd. Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
US20120309968A1 (en) * 2010-02-08 2012-12-06 Nan Jing Cavendish Bio-Engineering Technology Co., Ltd. Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
WO2013065063A1 (fr) 2011-11-03 2013-05-10 Cadila Healthcare Limited Forme anhydre du dasatinib, son procédé de préparation et son utilisation
WO2013078973A1 (fr) * 2011-11-29 2013-06-06 上海创诺制药有限公司 Dasatinib à grand diamètre des particules et sa préparation et son utilisation
CN102408423A (zh) * 2011-11-29 2012-04-11 上海希迪制药有限公司 一种制备大粒径达沙替尼的方法
CN102408423B (zh) * 2011-11-29 2013-12-25 上海希迪制药有限公司 一种制备大粒径达沙替尼的方法
WO2013157019A2 (fr) * 2012-04-20 2013-10-24 Shilpa Medicare Ltd. Procédé pour la préparation de dasatinib monohydraté
WO2013157019A3 (fr) * 2012-04-20 2013-12-19 Shilpa Medicare Ltd. Procédé pour la préparation de dasatinib monohydraté
US9145406B2 (en) 2012-04-20 2015-09-29 Shilpa Medicare Limited Process for preparing dasatinib monohydrate
CN103709156B (zh) * 2012-09-29 2016-08-03 石药集团中奇制药技术（石家庄）有限公司 一种达沙替尼多晶型药物及其制备方法
CN103709156A (zh) * 2012-09-29 2014-04-09 石药集团中奇制药技术（石家庄）有限公司 一种达沙替尼多晶型药物及其制备方法
WO2014086326A1 (fr) * 2012-12-06 2014-06-12 Zentiva, K.S. Procédé pour la préparation et la purification de polymorphes et solvates nouveaux et connus du dasatinib
CZ306598B6 (cs) * 2012-12-06 2017-03-22 Zentiva, K.S. Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu
CN103408542B (zh) * 2013-08-13 2016-06-29 南京优科生物医药研究有限公司 一种高纯度的达沙替尼无水物的制备方法
CN103408542A (zh) * 2013-08-13 2013-11-27 南京优科生物医药研究有限公司 一种高纯度的达沙替尼无水物的制备方法
WO2015107545A1 (fr) * 2013-12-18 2015-07-23 Dharmesh Mahendrabhai Shah Sels solubles dans l'eau d'hydrate de dasatinib
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
WO2018100585A1 (fr) * 2016-12-01 2018-06-07 Natco Pharma Limited Procédé amélioré de préparation de polymorphe de dasatinib
US10800771B2 (en) 2016-12-01 2020-10-13 Natco Pharma Limited Process for the preparation of dasatinib polymorph
WO2019209908A1 (fr) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Formes cristallines de dasatinib
US11440908B2 (en) 2018-04-25 2022-09-13 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US11007195B2 (en) 2018-06-15 2021-05-18 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11052088B2 (en) 2018-06-15 2021-07-06 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11160805B2 (en) 2018-06-15 2021-11-02 Handa Onocology, Llc Kinase inhibitor salts and compositions thereof
US10869836B1 (en) 2019-05-17 2020-12-22 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10874613B1 (en) 2019-05-17 2020-12-29 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10874614B1 (en) 2019-05-17 2020-12-29 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10894017B1 (en) 2019-05-17 2021-01-19 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10894018B1 (en) 2019-05-17 2021-01-19 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10869837B1 (en) 2019-05-17 2020-12-22 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US11344500B2 (en) 2019-05-17 2022-05-31 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US11833249B2 (en) 2019-05-17 2023-12-05 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Also Published As

Publication number Publication date
WO2010139979A3 (fr) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2010139979A2 (fr) Procédés d'élaboration de formes cristallines
WO2010139981A2 (fr) Procédés d'élaboration de formes cristallines
US11149017B2 (en) Solid state forms of apalutamide
WO2010139980A1 (fr) Procédé de préparation d'un monohydrate de dasatinib cristallin
WO2011095059A1 (fr) Polymorphes du dasatinib, leurs procédés de préparation et leurs compositions pharmaceutiques
US11384077B2 (en) Solid state form of Valbenazine
WO2011033307A1 (fr) Sel de dichlorhydrate de nilotinib
WO2015181573A1 (fr) Sels de dasatinib
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2018073574A1 (fr) Formes polymorphes de palbociclib
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
US9255063B2 (en) Colchicine solid-state forms; methods of making; and methods of use thereof
US10071999B2 (en) Crystalline forms of (3-amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
EP3830091A1 (fr) Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
WO2020053795A2 (fr) Procédé de préparation d'acalabrutinib et de ses intermédiaires
JP2002510625A (ja) Ｍｒｐ１の阻害方法
WO2020053660A1 (fr) Formes solides d'un inhibiteur de bet
EP1907379A1 (fr) Formes cristallines de monohydrochlorure de (2r-trans)-6-chloro-5ýý4-ý(4-fluorophenyl)methyl¨-2,5-dimethyl-1-piperazinyl¨carbonyl¨-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide
US20220119415A1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US20220119414A1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
KR20210135530A (ko) Flna-결합 화합물 및 이의 하이드로클로라이드 염의 고체 다형체
WO2023222946A1 (fr) Procédé de préparation de cabozantinib
CA3230314A1 (fr) Formes solides d'inhibiteurs de bcl-2, procede de preparation et utilisation correspondante
WO2016145269A1 (fr) Formes solides de lédipasvir et procédés pour la préparation de lédipasvir
HU231012B1 (hu) Lapatinib sók

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722771

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10722771

Country of ref document: EP

Kind code of ref document: A2